Skip to content

Study · Systematic review · 2025

4 results

Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.

Chen J, Zhang Q, Wu Q, Zhang X, Xiang Z, Zhu S, Dai T, Si Y

Journal of diabetes1 Sept 2025Cited by 8 (Europe PMC)

PMID40887719 (opens in a new tab)PMCIDPMC12399406 (opens in a new tab)DOI10.1111/1753-0407.70151 (opens in a new tab)PepBankPUB-40887719
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundThis meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.MethodsA comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases. The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.ResultsThis meta-analysis included data from 25 randomized controlled trials (RCTs). The results indicated no significant difference in the incidence of suicidal behavior between the GLP-1 RA exposure group and the control group (RR = 0.84, 95% CI: 0.54-1.32, p = 0.46, I2 = 0%). Subgroup analysis showed no significant differences in the incidence of suicidal behavior among participants with T2DM (RR = 0.74), obesity (RR = 1.07), adolescents (RR = 0.91), and adults (RR = 0.84). Additionally, no significant differences were observed between the two groups in any type of suicidal behavior, including suicidal ideation (RR = 1.04), suicide attempts (RR = 0.68), depression-related suicides (RR = 0.65), and completed suicides (RR = 1.06). There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92). No significant differences were observed between the exposure group and control group according to different comparators, including placebo (RR = 0.91) and others (RR = 1.08). All subgroup analyses showed p-values greater than 0.05 (two-sided tests) and I2 values of 0%.ConclusionOur findings suggest that there is no significant association between GLP-1 RA exposure and suicidal behaviors in patients with T2DM or obesity.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a subgroup meta-analysis, liraglutide showed no significant difference in suicidal behavior versus control (RR 0.92).

    In plain wordsIn T2D or obesity studies, liraglutide showed no significant suicidal-behavior difference versus controls.

    Peptide
    Liraglutide
    Outcome
    No significant changeSuicidal behavior incidence
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.92
    native subgroup versus controls
    Reported subgroup P-value
    > 0.05
    source global qualification of all subgroup tests; not overall P
    I2
    0%
    reported qualification of all subgroup analyses

    Source sentences

    Summary
    There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92).
    4 context sentences
    Summary · context
    This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.
    Summary · context
    A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases.
    Summary · context
    The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.
    Summary · context
    All subgroup analyses showed p-values greater than 0.05 (two-sided tests) and I2 values of 0%.
  2. 02HumanSystematic reviewSafety outcome

    In a subgroup meta-analysis, semaglutide showed no significant difference in suicidal behavior versus control (RR 0.82).

    In plain wordsIn T2D or obesity studies, semaglutide showed no significant suicidal-behavior difference versus controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeSuicidal behavior incidence
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.82
    native subgroup versus controls
    Reported subgroup P-value
    > 0.05
    source global qualification of all subgroup tests; not overall P
    I2
    0%
    reported qualification of all subgroup analyses

    Source sentences

    Summary
    There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92).
    4 context sentences
    Summary · context
    This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.
    Summary · context
    A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases.
    Summary · context
    The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.
    Summary · context
    All subgroup analyses showed p-values greater than 0.05 (two-sided tests) and I2 values of 0%.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In people with type 2 diabetes or obesity, pooled GLP-1 receptor agonists including liraglutide showed no significant difference in suicidal behavior versus control (RR 0.84, 95% CI 0.54-1.32).

    In plain wordsIn T2D or obesity trial pools including liraglutide, suicidal behavior incidence showed no significant difference versus controls.

    Peptide
    Liraglutide
    Outcome
    No significant changeSuicidal behavior incidence
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Mental health and mood

    Measurements

    Risk ratio
    0.84
    pooled class versus controls
    95% CI
    0.54 to 1.32
    pooled class versus controls
    P-value
    0.46
    overall pooled suicidal behavior
    I2
    0%
    overall heterogeneity

    Source sentences

    Summary
    The results indicated no significant difference in the incidence of suicidal behavior between the GLP-1 RA exposure group and the control group (RR = 0.84, 95% CI: 0.54-1.32, p = 0.46, I2 = 0%).
    4 context sentences
    Summary · context
    This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.
    Summary · context
    A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases.
    Summary · context
    The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.
    Summary · context
    There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In people with type 2 diabetes or obesity, pooled GLP-1 receptor agonists including semaglutide showed no significant difference in suicidal behavior versus control (RR 0.84, 95% CI 0.54-1.32).

    In plain wordsIn T2D or obesity trial pools including semaglutide, suicidal behavior incidence showed no significant difference versus controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeSuicidal behavior incidence
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Mental health and mood

    Measurements

    Risk ratio
    0.84
    pooled class versus controls
    95% CI
    0.54 to 1.32
    pooled class versus controls
    P-value
    0.46
    overall pooled suicidal behavior
    I2
    0%
    overall heterogeneity

    Source sentences

    Summary
    The results indicated no significant difference in the incidence of suicidal behavior between the GLP-1 RA exposure group and the control group (RR = 0.84, 95% CI: 0.54-1.32, p = 0.46, I2 = 0%).
    4 context sentences
    Summary · context
    This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity.
    Summary · context
    A comprehensive search of electronic databases, including PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov, was conducted from the inception of the databases.
    Summary · context
    The risk ratio (RR) and 95% confidence intervals (95% CI) were calculated.
    Summary · context
    There were also no significant differences between the groups for any type of GLP-1 RA, including dulaglutide (RR = 0.46), exenatide (RR = 0.98), semaglutide (RR = 0.82), lixisenatide (RR = 1.25), and liraglutide (RR = 0.92).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 5Current

    27 Oct 2026, 16:36 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 18:59 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 3

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.